NCT02158858 - A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies | Biotech Hunter

Enrollment

336

Participants

Timeline

Start Date

July 16, 2014

Primary Completion Date

January 9, 2025

Study Completion Date

January 9, 2025

Conditions

MyelofibrosisLeukemia, Myelocytic, AcuteMyelodysplastic/Myeloproliferative NeoplasmMyelodysplastic Syndrome (MDS)PreleukemiaPrimary MyelofibrosisMyeloproliferative DisordersBone Marrow DiseaseHematological DiseasePrecancerous ConditionsNeoplasmsLeukemiaNeoplasms by Histologic TypeEssential Thrombocytosis

Interventions

DRUG

Pelabresib

CPI-0610 is administered orally once daily for 14 consecutive days, followed by a 7-day break (1 cycle = 21 days)

DRUG

Ruxolitinib

Ruxolitinib is given orally, twice daily (BID), on a continuous basis for 21 consecutive days of each 21-day cycle.

Trial Locations (48)

2060

ZNA Stuyvenberg Antwerpen, Antwerp

3000

UZ Leuven - Campus Gasthuisberg, Leuven

8000

AZ Sint-Jan Burgge-Oostende AV- Campus Sint-Jan, Bruges

10021

Memorial Sloan Kettering Cancer Center, New York

10029

ICAHN School of Medicine at Mount Sinai, New York

10065

Weill Medical College and New York Presbyterian Hospital, New York

16132

AOU S.Martino, IRCCS, IST-Istituto Nazionale Ricerca Sul Can, Genoa

20122

Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda, Milan

21100

Ospedale di Circolo, PO Varese, AO Ospedale di Circolo e Fon, Varese

27100

IRCCS Policlinico San Matteo, Università degli studi di Pavi, Pavia

28100

AOU Maggiore della Carità, Novara

30029

Institut de cancérologie du Gard - Hematologie clinique, Nîmes

31059

CHRU de Lille - Hopital Claude Huriez, Toulouse

32224

Mayo Clinic Jacksonville, Jacksonville

40138

"Institue of Hematology L. and A. Seràgnoli", Bologna

47923

Servizio Sanitario Regionale Emilia-Romagna - Azienda Unita Sanitaria Locale (AUSL) di Rimini - Ospedale Infermi di Rimini, Rimini

48109

University of Michigan Medical Center, Ann Arbor

50134

Azienda Ospedaliero-Universitaria Careggi, Florence

53127

Universitätsklinikum Bonn, Bonn

53226

Froedtert & Medical College of Wisconsin, Milwaukee

59037

CHRU de Lille - Hopital Claude Huriez - Maladies du Sang, Lille

60611

Northwestern University - Lurie Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicne Neuromuscular Division Department of Neurology Research, St Louis

75010

CHU - Hopital Saint Louis - Centre D'Investigations Clinique, Paris

77030

The University of Texas MD Anderson Cancer Center, Houston

85054

Mayo Clinic Arizona, Phoenix

90095

UCLA Medical Center, Los Angeles

94805

Institut Gustave Roussy, Villejuif

02114

Massachusetts General Hospital Cancer Center, Boston

T6G 2G3

University of Alberta Hospital, Edmonton

V6Z 2A5

St. Paul's Hospital, Vancouver

L8V 5C2

Juravinski Cancer Centre, Hamilton

M5G 2M9

Princess Margaret Cancer Centre, Toronto

H3T 1E2

Jewish General Hospital, Montreal

04103

Universitätsklinikum Leipzig AöR, Leipzig

6229 HX

Maastricht University Medical Center, Maastricht

1081 HV

VUmcResearch B.V., Amsterdam

3015 AA

Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam

02-776

Instytut Hematologii i Transfuzjologii w Warszawie, Warsaw

80-952

Uniwersyteckie Centrum Kliniczne, Gdansk

OX3 7LE

Oxford University Hospitals, Headington

BT9 7AB

Belfast City Hospital, Belfast

CB2 0QQ

University of Cambridge, Cambridge

CF14 4XW

University Hospital of Wales, Cardiff

G12 0YN

Beatson West of Scotland Cancer Centre, Glasgow

NW1 2PG

University College London Hospital's NHS foundation Trust, London

SE1 9RT

Guys and St Thomas' Hospital - Haematology, London

M20 4BX

The Christie Hospital, Manchester